Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acute hepatic failure
was induced experimentally in rats by intraperitoneal injection of 2.5 mL kg(-1) carbon tetrachloride (CCl4), and the effects on the expression and function of
P-glycoprotein
in the liver, kidney and brain were evaluated. The CCl4 injection significantly increased the indicators of hepatic function (glutamate oxaloacetate transaminase, glutamate pyruvate transaminase), but not of renal function (blood urea nitrogen, glomerular filtration rate). In rats with acute hepatic failure, the hepatic
P-glycoprotein
concentration increased 1.5-fold and the ATP concentration decreased to approximately 40% that in control rats. In contrast,
P-glycoprotein
concentrations in the kidney and brain and ATP concentrations in the kidney remained unchanged. The in-vivo
P-glycoprotein
function in these tissues was suppressed as evaluated by biliary and renal secretory clearances and brain distribution of rhodamine 123, a
P-glycoprotein
substrate. These findings suggest that factors other than
P-glycoprotein
concentration are involved in the systemic suppression of
P-glycoprotein
function in diseased rats. In Caco-2 cells, plasma collected from CCl4-treated rats exhibited a greater inhibitory effect on
P-glycoprotein
-mediated transport of rhodamine 123 than that from control rats, suggesting the accumulation of an endogenous
P-glycoprotein
substrate/inhibitor in the plasma of diseased rats. In fact, the plasma concentration of corticosterone, an endogenous
P-glycoprotein
substrate, increased 2-fold in CCl4-treated rats compared with control rats. It was demonstrated that
P-glycoprotein
function is systemically suppressed in rats with CCl4-induced acute hepatic failure, not only in the target organ (liver), but also in other organs (kidney and brain), although the
P-glycoprotein
concentration remained unchanged in the kidney and brain, and increased in the liver. In the systemic suppression of the
P-glycoprotein
function in the diseased state, the alteration of plasma concentrations or components of endogenous
P-glycoprotein
-related compounds, such as corticosterone, would likely be involved.
...
PMID:Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. 1142 64